Antimicrobial Peptide GPR15L, Dipeptidyl Peptidase-4, and Glucagon-Like Peptide-2 in Relation to Disease Activity in Ulcerative Colitis: A Cross-Sectional Case–Control Study in a Single Iraqi Referral Centre

Background and Aims: GPR15L (encoded by GPR15LG/C10orf99) is a colon-restricted peptide that combines direct antimicrobial activity with chemoattractant signalling through GPR15, whereas dipeptidyl peptidase-4 (DPP-4) and its substrate glucagon-like peptide-2 (GLP-2) govern epithelial repair. Whether these three mediators behave as a coordinated epithelial axis across the activity spectrum of ulcerative colitis (UC), has not been established in a single patient cohort spanning mild, moderate-to-severe and quiescent disease. Methods: One hundred and twenty participants were enrolled: 30 with moderate-to-severe active UC, 30 with mildly active UC, 30 with UC in clinical and endoscopic remission, and 30 healthy controls. Serum GPR15L, serum DPP-4 concentration, plasma DPP-4 enzymatic activity and total immunoreactive GLP-2 were quantified by enzyme-linked immunosorbent assay. Faecal calprotectin was measured by ELISA. Disease activity was graded by the total Mayo score and the Mayo endoscopic subscore (MES). Group comparisons, Spearman correlation, receiver-operating-characteristic (ROC) analysis and multivariable logistic regression were performed. Results: Serum GPR15L decreased stepwise with increasing disease activity (median 184, 268, 395 and 448 pg/mL in moderate-to-severe UC, mild UC, remission and controls, respectively; P < 0.001). Serum DPP-4 and plasma DPP-4 activity showed the same downward gradient, whereas total immunoreactive GLP-2 rose progressively (38.6 ± 11.4 versus 16.9 ± 5.1 pmol/L; P < 0.001) and correlated inversely with DPP-4 (ρ = −0.55). GPR15L correlated inversely with the total Mayo score (ρ = −0.68), the Mayo endoscopic subscore (ρ = −0.64), faecal calprotectin (ρ = −0.71) and C-reactive protein (ρ = −0.46; all P < 0.001). For discriminating active disease from remission, GPR15L achieved an area under the curve (AUC) of 0.88 (cut-off ≤ 312 pg/mL; sensitivity 86.7%, specificity 83.3%); a three-marker composite reached an AUC of 0.94, against 0.93 for faecal calprotectin. All three mediators remained independent predictors of disease activity after adjustment for age, sex and body mass index. Conclusions: Active UC is characterised by concurrent depletion of the colonic antimicrobial peptide GPR15L and of DPP-4, accompanied by an accumulation of circulating GLP-2 that is consistent with reduced enzymatic inactivation together with an unmet reparative demand. GPR15L tracks the activity gradient more closely than either of the other two mediators and merits evaluation as a serum marker of colonic epithelial integrity alongside faecal calprotectin.

Authors

Institutions

Publication Details

Journal
NIU Journal of Health Sciences
Published
2026-11-16
DOI
https://doi.org/10.58709/niujhs.v12i3.2770
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antimicrobial Peptide GPR15L, Dipeptidyl Peptidase-4, and Glucagon-Like Peptide-2 in Relation to Disease Activity in Ulcerative Colitis: A Cross-Sectional Case–Control Study in a Single Iraqi Referral Centre

Hiba Ahmed Mahmood
4 links
NIU Journal of Health Sciences
Inflammatory Bowel Disease
article

Antimicrobial Peptide GPR15L, Dipeptidyl Peptidase-4, and Glucagon-Like Peptide-2 in Relation to Disease Activity in Ulcerative Colitis: A Cross-Sectional Case–Control Study in a Single Iraqi Referral Centre

Hiba Ahmed Mahmood
article en

Abstract

Background and Aims: GPR15L (encoded by GPR15LG/C10orf99) is a colon-restricted peptide that combines direct antimicrobial activity with chemoattractant signalling through GPR15, whereas dipeptidyl peptidase-4 (DPP-4) and its substrate glucagon-like peptide-2 (GLP-2) govern epithelial repair. Whether these three mediators behave as a coordinated epithelial axis across the activity spectrum of ulcerative colitis (UC), has not been established in a single patient cohort spanning mild, moderate-to-severe and quiescent disease. Methods: One hundred and twenty participants were enrolled: 30 with moderate-to-severe active UC, 30 with mildly active UC, 30 with UC in clinical and endoscopic remission, and 30 healthy controls. Serum GPR15L, serum DPP-4 concentration, plasma DPP-4 enzymatic activity and total immunoreactive GLP-2 were quantified by enzyme-linked immunosorbent assay. Faecal calprotectin was measured by ELISA. Disease activity was graded by the total Mayo score and the Mayo endoscopic subscore (MES). Group comparisons, Spearman correlation, receiver-operating-characteristic (ROC) analysis and multivariable logistic regression were performed. Results: Serum GPR15L decreased stepwise with increasing disease activity (median 184, 268, 395 and 448 pg/mL in moderate-to-severe UC, mild UC, remission and controls, respectively; P < 0.001). Serum DPP-4 and plasma DPP-4 activity showed the same downward gradient, whereas total immunoreactive GLP-2 rose progressively (38.6 ± 11.4 versus 16.9 ± 5.1 pmol/L; P < 0.001) and correlated inversely with DPP-4 (ρ = −0.55). GPR15L correlated inversely with the total Mayo score (ρ = −0.68), the Mayo endoscopic subscore (ρ = −0.64), faecal calprotectin (ρ = −0.71) and C-reactive protein (ρ = −0.46; all P < 0.001). For discriminating active disease from remission, GPR15L achieved an area under the curve (AUC) of 0.88 (cut-off ≤ 312 pg/mL; sensitivity 86.7%, specificity 83.3%); a three-marker composite reached an AUC of 0.94, against 0.93 for faecal calprotectin. All three mediators remained independent predictors of disease activity after adjustment for age, sex and body mass index. Conclusions: Active UC is characterised by concurrent depletion of the colonic antimicrobial peptide GPR15L and of DPP-4, accompanied by an accumulation of circulating GLP-2 that is consistent with reduced enzymatic inactivation together with an unmet reparative demand. GPR15L tracks the activity gradient more closely than either of the other two mediators and merits evaluation as a serum marker of colonic epithelial integrity alongside faecal calprotectin.

NIU Journal of Health SciencesVol. 12(3)
University of Samarra (IQ)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon